DESCUBRA TODOS LOS DETALLES SOBRE ESTOS PROYECTOS

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
CARLOS AYÁN PÉREZ	Faculty of Education and Sport Science Department of Special Didactics University of Oviedo	A cluster-randomized cross-over repeated measures pilot study of the effect of Nordic Walking on cardiovascular fitness in young persons with Down síndrome	2019
NIEVES PIZARRO	Fundació Institut Mar d'Investigacions Mèdiques (IMIM) Integrative pharmacology and systems neuroscience Barcelona	Modulation of gut microbiota as a therapeutic approach to improve cognitive phenotypes of Ts65Dn mice and decelerate the onset of neurodegenerative processes	2019
SERGI CUARTERO	Josep Carreras Leukaemia Research Institute (IJC) Cancer Epigenetics and Biology Program (PEBC) Transcriptional dynamics in leukemia Badalona, Barcelona	Myeloid leukemia in Down syndrome: exploring the interplay between transcriptional regulation and immune signalling	2019
SUSANA DE LA LUNA	Center for Genomic Regulation (CRG) Gene Regulation, Stem cells and Cancer Lab. of Signaling and transcriptional regulation Barcelona, Espagne	Organization of the DYRK1A interactome through docking domains: searching for novel targeting approaches	2019
MARCOS MANZANEQUE PRADALES	Fundación para la Investigación Biomédica del Hospital Universitario de la Princesa	Study of neurohumoral pathways (Renin-Angiotensin-Aldosterone System, Neprilysin pathway and Neural Growth Factor) in adults with Down syndrome and optimization of the clinical management of their vascular risk	2019

FUNDACIÓN Jérôme Lejeune
Delegación en España

TODA UNA VIDA DEDICADA A LA INVESTIGACIÓN

Más de **70 proyectos** desarrollados en centros de investigación españoles

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
CRISTINA RODRÍGUEZ RODRÍGUEZ	Centro Nacional de Biotecnología (CNB-CSIC)	SNX27 deficiency contribution to inflammatory immune responses and its impact on Down syndrome associated pathologies	2018
ANNA VAZQUEZ OLIVER	Ciencias Experimentales y de la Salud . Universidad Pomeu y Fabra.	Abordajes preclínicos en el tratamiento del Síndrome de Down	2018
MARIA DEL MAR DIERSSEN SOTOS	President of the T21 Research Society Centre for Genomic Regulation (CRG)Lab. of Cellular & Systems Neurobiology	3rd International Meeting of the Trisomy 21 Research Society	2018
SANDRA GIMÉNEZ BADÍA	Hospital de la Santa Creu y Sant Pau Institut d'Investigacio Biomèdica Sant Pau	The impact of Alzheimer's disease on sleep in adults with Down síndrome	2018
MARIA VICTORIA PUIG VELASCO	IMIM- Hospital del Mar Medical Research Institute Dept.Farmacología Integrada y Neurociencia de Sistemas (FINS)	Neural activity patterns underlying cognitive normalization by EGCG and GABAa α5IA in the Ts65Dn mouse model of Down síndrome	2018
PALOMA APARICIO	Unidad de Atención a Adultos con Sindrome de Down (MIH-UPDOWN) Hospital Universitario de La Princesa	Patterns and causes of hospital admission, comorbiditles and mortality of Spanish adultswith Down Syndrome 2005-20014	2018
VICTORIA CAMPUZANO	Universidad Pomeu Fabra Departamento de Ciencias Experimentales y de la Salud Genética	Molecular bases in the effectiveness of the Williams Beuren syndrome by inhibitors of the monoacyl glycerol lipase	2018
MARÍA JOSÉ BARALLOBRE	CRG/UInstituto de Bilogía Molecular de Barcelona IBMB-CSIC y Centro de Investigación deEnfermedades Raras (CIBERER)PF Proteomics Unit	Identifying new mechanisms by which DYRK1A regulates the expansion of the cerebral cortex	2017
TERESA VARGAS ALDECOA	Universidad Villanueva	COMDIDOWN. Estudio de la comunicación del diagnóstico del Síndrome de Down de los profesionales sanitarios	2017

FUNDACIÓN Jérôme Lejeune
Delegación en España

TODA UNA VIDA DEDICADA A LA INVESTIGACIÓN

2.568.805 € destinados a la investigación en España

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
NOEMÍ RUEDA	Laboratory of Neurobiology of Learning and Memory Department of Physiology and Pharmacology University of Cantabria Santander	Effects of the normalization of Dyrk1a copy number on the cerebellar phenotypes and neurodegenerative profile of a mouse model of Down síndrome	2016
NIEVES PIZARRO	Integrative pharmacology and systems neuroscience Fundació Institut Mar d'Investigacions Mèdiques (IMIM)	Evaluation of dose and source of green tea extracts as contributing factors to treatment efficacy and hepatotoxicity. Therapeutic implications in Down syndrome	2016
MARIAN MARTÍNEZ-BALBÁS	Molecular Biology Institute from Barcelona IBMB - CSIC Cell Biology	Impact of epigenetic defects during neurodevelopment in intellectual disability: role of the histone demethylase PHF8	2016
MANEL ESTELLER BADOSA	Cancer Epigenetics Laboratory Bellvitge Biomedical Research Institute (IDIBELL) Cancer Epigenetics and Biology Program (PEBC) Hospital Duran i Reynals	New pharmacological therapies in Rett syndrome: the inflammation pathway mediated by GSK3	2016
STEPHAN OSSOWSKI	Genomics and Epigenomic Variation in Disease group Center for Genomic Regulation Bioinformatics Programme	EpiGenetic Change Generator in Down Syndrome	2016
MARIA VICTORIA PUIG VELASCO	Neuromodulation of neural networks and circuits IMIM- Hospital del Mar Medical Research Institute Integrated Pharmacology and Systems Neuroscience Dr. Aiguader 88, Barcelona 08003	Neural activity patterns of cognitive normalization mediated by environmental enrichment and epigallocatechin-3-gallate in a murine model of Down syndrome	2015
UGO MAYOR	Neuronal Ubiquitination Lab UPV / EHU Department of Biochemistry Sarriena Auzoa S/N, Leioa 48940	Partners of UBE3A as therapeutical targets: identifying the E2 and DUB enzymes involved in Angelman Syndrome	2015
MONK DAVID	Genomic Imprinting and Cancer Bellvitge Institute for Biomedical Research (IDIBELL) Cancer Epigenetics and Biology Program (PEBC) Hospital Duran i Reynals Av de la Granvia de l'Hospitalet 199-203, Barcelona 8907	Correcting imprinting errors using epigenetic editing tools	2015
EDUARD SABIDÓ	CRG/UPF Proteomics Unit Fundació Centre de Regulació Genòmica Core facilities-Fundació Centre de Regulació Genòmica Dr. Aiguader, 88, Planta 5Barcelona 08003	Elucidation of the mechanism of action of epigallocatechin-3-gallate as a therapeutic agent on the cognitive phenotype in Down Syndrome mice models.	2014

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
JAVIER GARCÍA ALBA	Unité pour les adultes avec le Trisomie 21 hôpital universitaire "la Princesa" Département de médecine interne C/ Diego de León, 62.Madrid 28006	Clinical, neuroanatomical and functional study in Down Syndrome population with and without dementia: predictive patterns for the development of dementia	2014
MARIA LUZ MONTESINOS	Synaptic Local Translation Lab Universidad de Sevilla Departemento de Fisiología Médica y Biofísica Av. Sanchez-Pizjuan, 4, Sevilla 41009	Maladie d'Alzheimer dans la trisomie 21: rôle de la traduction locale de l'ARNm APP	2014
CRISTINA FILLAT	TERGEN Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Rosselló 149-153, Barcelona 0803	Identification of functional pathways involving miR-155 and miR-802 chromosome 21 miRNAs participating in Down Syndrome brain ageing	2014
ANDRES OZAITA	Neuropharmacology Unit Universitat Pompeu Fabra Department of Experimental and Health Sciences Carrer del Dr. Aiguader, 88 Barcelona Biomedical Research Park (PRBB) Barcelona 08003	Study of the pharmacological blockade of type 1 cannabinoid receptors in the behavioral and biochemical characteristics of two animal models of Down syndrome.	2013
MANEL ESTELLER BADOSA	Cancer Epigenetics Laboratory Bellvitge Biomedical Research Institute (IDIBELL) Cancer Epigenetics and Biology Program (PEBC) Hospital Duran i Reynals Av. Gran Via de l' Hospitalet 199-203, 3rd floor Barcelona 08908 / L'Hospitalet de Llobregat	Preclinical assays in the treatment of Rett syndrome	2013
NOEMI RUEDA	Laboratory of Neurobiology of Learning and Memory University of Cantabria Department of Physiology and Pharmacology Faculty of Medicine c/ Cardenal Herrera Oria s/n, Santander 39011	Effects of chronic melatonin administration on the neurodevelopmental alternations and neurodgeneration in a mouse model of Down syndrome	2013
PETER MCCORMICK	Laboratory of Molecular Neurobiology University of Barcelona Department of Biochemistry 643 Avenida Diagonal, planta -2 Barcelona 08028	Validation of mGluR1/5 - Histamine 3 receptor heterodimers as novel targets to treat Fragile X Syndrome.	2012
MARIA LOURDES ARBONÉS DE RAFAEL	Nervous system, proliferation and differentiation Institut de Biologia Molecular de Barcelona, Consejo Superior de Investigaciones Científicas (CSIC) Department of Developmental Biology IBMB-CSIC, Barcelona Cientific Park c/ Baldiri Reixac 4-8 Torre R, 3era planta, Barcelona 08028	Deciphering how triplication of DYRK1A impacts in early brain neurogenesis	2012
MARIA DEL MAR DIERSSEN SOTO	Center for Genomic Regulation Barcelona Biomedical Research Park Cell and Developmental Biology Dr. Aiguader, 88, Barcelona 08003	The role of Dyrk1A in Down syndrome obesity: mechanism and therapeutic approaches	2012
EMILIO VAREA	Cellular Neurobiology, University of Valencia Cell Biology and Parasitology Doctor Moliner, 50, Campus de Burjassot, Edificio B, 4 planta. Burjassot 46100	Early treatment with tiagabine, a selective GABA uptake inhibitor, to prevent alterations in the mice model for Down Syndrome Ts65Dn	2012
FRANCISCO J. TEJEDOR	Molecular Neurogenetics Instituto de Neurociencias. CSIC and UMH Dept. Developmental Neurobiology Instituto de Neurociencias Univ.Miguel Hernandez Campus de San Juan, Sant Joan Alicante 3550	Involvement of SEPT4 phosphorylation by MNB/DYRK1A in neurite formation and dendritogenesis/synaptogenesis. Implications for Trisomy 21 and pharmacotherapeutics	2012
MARIAN MARTÍNEZ-BALBÁS	Molecular Biology Institute from Barcelona IBMB - CSIC Cell Biology C/ Baldiri i Reixac 15-21 Barcelona 08028	Epigenetic defects in mental retardation: role of the histone demethylase PHF8	2012

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
XAVIER ALTAFAJ TARDIO	Neurobiology of Ionotropic Glutamate Receptors Bellvitge Biomedical Research Institute Institute of Neuropathology Av. Gran Via de l'Hospitalet, 199-203 L'Hospitalet de Llobregat, Barcelona 08908	Study of excitatory-inhibitory neurotransmission imbalance in Ts65Dn mouse model of Down syndrome.	2011
MARIA V. SANCHEZ-VIVESL	Systems Neuroscience IDIBAPS Roselló 149-153 Barcelona 080363	Understanding brain network alteration leading to cognitive impairment in Down syndrome and identification of new therapeutic tragets	2011
RAFAEL DE LA TORRE FORNELL	Fundació Institut Mar d'Investigacions Mèdiques IMIM Human Pharmacology and Clinical Neurosciences Parc de Recerca Biomèdica de Barcelona C/ Doctor Aiguader 88 Barcelona 08003	Normalization of dyrk1A function as an approach to improve cognitive performance in SD subjects: Epigallocatechin gallate as therapeutic tool	2011
MARIA LUZ MONTESINOS	Synaptic Local Translation Lab Université de Séville Departamento de Fisiología Médica y Biofísica Av. Sanchez-Pizjuan, 4 Sevilla 41009	Potencial de la rapamycina para el tratamiento de las déficiencias cognitivas de la trisomíe 21	2011
EMILIO VAREA	Cellular Neurobiology University of Valencia Cell Biology and Parasitology Doctor Moliner, 50, Campus de Burjassot, Edificio B, 4 planta, Burjassot 46100	Alterations in hippocampal granule neurons of Ts65Dn mice. Neurite extension promoter treatment to recover cognitive status in Down Syndrome	2010
MARÍA DEL MAR DIERSSEN SOTO	Fundació Centre de Regulació Genòmica Neurobehavioral Phenotyping of Mouse Models of Dis Dr. Aiguader 88, Barcelona 8003	Synaptic drugs for cognitive disorders: identifying new targets for pharmacological intervention	2010
RAFAEL DE LA TORRE FORNELL	Fundació Institut Mar d'Investigacions Mèdiques IMIM. Human Pharmacology and Clinical Neurosciences Parc de Recerca Biomèdica de Barcelona C/ Doctor Aiguader 88, Barcelona 08003	EGCG, a DYRK1A inhibitor as therapeutic tool for reversing cognitive deficits in Down syndrome individuals	2010
EDUARD SERRA-ARENAS	Joint Program ICO-IMPPC for Molecular Diagnostics Institute of Predictive and Personalized Medicine of Cancer. Carretera de Can Ruti. Cami de les Escoles s/n, Badalona 8916	Discovering new roles of Neurofibromin function in cell physiology through genetic interaction maps	2009
MANEL ESTELLER	Bellvitge Biomedical Research Institute (IDIBELL) Cancer Epigenetics and Biology Program (PEBC) Hospital Duran i Reynals Av. Gran Via de l' Hospitalet 199-203, 3rd floor Barcelona 08908 / L'Hospitalet de Llobregat	Rett Syndrome: How MeCP2 defects might lead to microRNA dysfunction	2009
YOLANDA DE DIEGO-OTERO	Neuropsychopharmacology of the Fragile-X Syndrome. Hospital Regional Universitario de Málaga. IBIMA. Fundación IMABIS Laboratorio de Investigación Hospital Civil, Pabellón 5 Sótano, Málaga 29009	Involvement of the Rac1-GTPase in the Fragile X syndrome: New experimental therapeutic target.	2009
SONJA UHLMANN	Fundación Síndrome Down Madrid Equipo de Investigación Fundación Síndrome Down Madrid C/ Caidos de la División Azul 21, Madrid 28016	BATERêA ECODI. Batería de evaluación cognitiva destinada a las personas afectas de deficiencia intelectual	2009
SUSANA DE LA LUNA	Gene Function Centre de Regulació Genòmica-CRG Genes and Disease Programme Dr. Aiguader 88, Barcelona 08003	Networking human chromosome 21 genes in Down syndrome	2009

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
CRISTINA FILLAT FONTS	Gene Therapy Fundació Privada Centre de Regulació Genòmica Genes and Disease Program Dr. Aiguader, 88, Barcelona 8003	Knockdown of HSA 21-syntenic miRNAs in Ts65Dn mice by adeno-associated viral vectors. Consequences on hippocampus-dependent phenotypes.	2009
FRANCISCO J. TEJEDOR	Instituto de Neurociencias. CSIC and UMH Dept. Developmental Neurobiology Sant Joan Alicante	Involvement of the MNB/DYRK1A kinase-SEPT4 interaction in Trisomy 21 associated Neuropathologies	2008
MARÍA LUZ MONTESINOS	Synaptic Local Translation Lab Universidad de Sevilla Departamento de Fisiología Médica y Biofísica Av. Sanchez-Pizjuán, 4, Séville 41009	Regulación de la traducción local sináptica de DSCAM, gen candidato de la trisomie 21	2008
CARMEN MARTÍNEZ-CUE	Laboratory of Neurobiology of Learning University of Cantabria Department of Physiology and Pharmacology c/ Cardenal Herrera Oria s/n Facultad de Medicina, Santander 39011	Study of the effect of physical exercise and of chronic administration of the inverse agonist selective for the a5 subunit of the GABAA receptor, a5IA	2008
EMILIO VAREA	Universidad Miguel Hernandez Thyroid hormones and development of the cerebral cortex Sant Joan d'Alacant	Alteration of inhibitory circuits in the Neo-cortex of the Ts65Dn mice model. Putative role of interneurons in mental retardation associated with DS	2008
MARÍA JOSÉ BARALLOBRE	Murine's models of disease Fundació Privada Centre de Regulació Genòmica, Genes and Disease Program C/ Dr. Aiguader, 88, Barcelona 8003	Role of Dyrk1A and DSCR1 during the development of cortical dendrites. Implications in Down Syndrome.	2007
MARÍA DEL MAR DIERSSEN SOTO	Centro de Regulación Genómica Genes and disease program Barcelona	Novel hypothesis driven therapeutic strategies for the reversion of Down syndrome cognitive phenotypes	2007
EMILIO VAREA	Universitat de Valencia Dpt de Biologia Celular Burjassot	Alterations of inhibitory circuits in Neo-cortex of Ts65Dn mice. Putative role of interneurons in mental retardation associated with Down Syndrome	2007
EULALIA MARTÍ	Genes and Disease Program Centro de Regulación Genómica Genetic Causes of Disease Biomedical Research Park C/Dr. Aiguader 88, Barcelona E-08003	Molecular mechanisms underlying RCAN1/DSCR1-mediated neuronal death and its relevance to Down syndrome and neurodegenerative diseases	2007
JUAN NACHER	Universitat de Valencia Dpt de Biologia Celular Doctor Moliner 50Campus de Burjassot, Edificio B 4 planta, Burjassot 46100	Alterations in structural plasticity in the Ts65Dn mice model. Implications in Down's Syndrome and possible recovery by fluoxetine treatment	2006
CRISTINA FILLAT FONTS	Center for Genomic Regulation Barcelona Biomedical Research Park Cell and Developmental Biology Barcelona	Functional and molecular consequences of inhibiting Dyrk1A gene expression in the hippocampus of Down syndrome mouse models by AAVshDyrk1A delivery.	2006
MARÍA MARTÍNEZ DE LAG CABREDO	Center for Genomic Regulation Barcelona Biomedical Research Park Cell and Developmental Biology Dr. Aiguader, 88, Barcelona 08003	Down syndrome candidate genes in the development of the neuropathological landmarks of Alzheimer disease	2006

INVESTIGADOR PRINCIPAL	LABORATORIO	TÍTULO DEL PROYECTO DE INVESTIGACIÓN	AÑO
MARÍA LUZ MONTESINOS	Synaptic Local Translation Lab Universidad de Sevilla Departemento de Fisiología Médica y Biofísica Av. Sánchez-Pizjuán, 4, Sevilla 41009	Rol del transporte y la traducción local del ARN mensajero dentrítico en la fisiopatología neuronal del Síndrome de Down	2005
MARA DIERSSEN	Centro de Regulacion Genómica Genetic Causes of Disease Barcelona	Desarrollo y análisis de la eficacia de intervenciones terapéuticas sobre la alteración cognitiva en los modelos murinos con trisomía 21	2004
MARA DIERSSEN	Centro de Regulacion Genomica Genetic Causes of Disease Barcelona	Rol del cortex cerebral en la capacidad cognitiva	2004
CARMEN MARTÍNEZ-CUE	Universidad de Cantabria, Facultad de Medicina Dpto. Fisiologia y Farmacologia Lab. of Developmental Neurobiology Avda. Cardenal Herrera Oria, 2, Santander 39011	Estudio del efecto terapeutico de los inhibidores de la acetylcolinesterasa y de GVS-111 sobre los déficit cognitivos, la neurogénesis de la apoptosa	2004
MARIA LOURDES ARBONES	Centre de Regulacio Genomica Genetic causes of diseases Dr. Aiguader, 88, 08003 Barcelona	Análisis del rol de Dyrk1A, un gen candidato en el retraso mental de la Trisomie 21	2004
GLORIA ARQUE	Genes and Disease Program Centro de Regulacion Genomica Genetic Causes of Disease Biomedical Research Park C/Dr. Aiguader 88, Barcelona E-08003	Caracterización de un modelo de murino de sobreexpresión de BACE2, una béta secretasa potencialmente implicada en los depósitos de béta amylo	2003
CRISTINA FILLAT	Centro de Regulacion Genomica Genetic Causes of Disease Barcelona	Consecuencias fenotípicas de la utilización de ARN interferente sobre Dyrk1a con modelos de murinos con trisomía 21. Implicaciones para la terapia	2003
JESÚS FLOREZ-BELEDO	Université de Cantabria Lab. of Developmental Neurobiology Santander	Estudio de los efectos farmacológicos y comportamentales sobre los déficits cognitivo y neuroquímico de ratones Ts65Dn, un modelo de trisomía 21	2002
LUIS ALBERTO PÉREZ JURADO	Universidad Pompeu Fabra Unidad de Genética Dr Aiguader, 88, Barcelona 8003	Estudio molecular del Syndrome de Williams: identificación de los genes relevantes en la ayuda del establecimiento de la correlación clínico molecula	2002
MARA DIERSSEN	Centro de Regulacion Genómica Genetic Causes of Disease Barcelona	10º encuentro internacional sobre la biología molecular del cromosoma 21 y el síndrome de la trisomia 21	2002
MARA DIERSSEN	Centro de Regulacion Genómica Genetic Causes of Disease Barcelona	Desarrollo y análisis de la eficacia de terapias sobre la alteración cognitiva de modelos murinos con trisomie 21	2001
XAVIER ESTIVILL	En 2000: Hopital Duran i Reynals - HIRO. Medical and Molecular Genetics Center Hospitalet del Llobregat, Barcelona Hoy en día: Centre for Genomic Regulation (CRG). Carrer del doctor Aiguader 88, 08003 Barcelona	Implicación de Dyrk1a en los defectos de aprendizaje asociados a la trisomía 21 y sus relaciones neurofarmacológicas	2000